X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
NCE Product Pipeline - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Jun 10, 2003

    NCE Product Pipeline

    In an earlier article, we had seen the different avenues open to Indian companies in the post – patent regime in 2005. We had stated that the most lucrative opportunity available to the Indian companies would from the development of a New Chemical Entity (NCE). (click here to know more on stages post NCE development).

    In this article, we shall see steps taken by various Indian companies towards strengthening the NCE portfolio through R&D and success achieved by them. To start with, consider Dr. Reddy’s Laboratory (DRL) NCE pipeline.

    Dr. Reddys Laboratory Ltd.
    Compound Therapeutic Area Development Status
    DRF 2725  Diabetes & Dyslipidemia Phase III (Clinical Trials
    Terminated)
    DRF 2593  Diabetes Phase II Completed
    DRF 1042  Cancer Phase I Completed
    DRF 4158  Metabolic disorders Preclinical completed
    (Novartis discontinues
    further development)
    DRF 1644  Cancer Preclinical Completed 
    DRF 4832  Metabolic disorders Late Preclinical
    DRF 10945  Metabolic disorders/
    Dyslipidemia
    Preclinical
    DRF 11057  Bacterial Infections Preclinical

    DRL has the largest number of NCEs in India, at various stages of clinical trials. The NCEs DRF-2725 and DRF-2593 have been licensed to Novo Nordisk and DRF-4158 to Novartis AG for carrying out clinical trials. In FY02, DRL received upfront and milestone payments (Rs 389 m) in respect of the DRF-2725 and DRF-4158, thereby contributing to the bottomline of the company. However, DRL’s research has had its share of failures as well. Clinical trials in respect of two of the three molecules licensed have been discontinued. Novo Nordisk terminated clinical trials for the NCE DRF-2725, while Novartis AG discontinued further development of DRF-4158. This has come as a major setback to DRL, as it would not be receiving any further milestone payments in respect of these two molecules.

    Ranbaxy Ltd.
    Compound Therapeutic Area Development Status
    RBx 2258 Benign Prostatic Hyperplasia (BPH) Phase I Completed
    RBx 7796 Bronchial Asthma Undergoing Phase I
    RBx 7644 Anti - Bacterial Undergoing Phase I
    RBx 6198 BPH Molecule Early Discovery Stage
    RBx 9611 Overactive Bladder Early Discovery Stage
    RBx 8700 Anti - Infective / Tuberculosis Early Discovery Stage

    Ranbaxy is also increasingly focusing on new drug discovery. The company has licensed its NCE RBx-2258 to Schwarz Pharma, which is currently undergoing Phase 2 clinical trials. Besides Ranbaxy has five more molecules in the Phase 1 of clinical trials and in early discovery stages. Among other companies, Wockhardt Ltd’s anti–infective molecule WCK-771 is undergoing Phase 1 clinical trial.

    Thus, from the above article we observe that India has been adopting the strategy of developing an NCE and licensing the same to foreign companies for further development. This is a step in the right direction, as Indian companies lack the resources to completely develop a new drug. However, going forward, once the Indian companies succeed in licensing few NCEs and develop critical mass, they will be in a position to develop the NCE on their own.

    Having said that we must also inform the reader that the drug discovery process is long drawn and expensive. It takes between 8 to 10 years and US$ 350 m to US$ 500 m for an NCE to reach the commercial stage. This apart, the likelihood of an NCE failing at any of the various stages of clinical trials is also high. For every 5 NCEs evaluated, only one receives final FDA approval. Hence, considering that the drug licensing process is not devoid of failures, we could expect negative news on this front as has been seen in the past (DRF-2725). But the important point is that Indian companies are gradually moving up the value chain despite the recent setbacks.

     

     

    Equitymaster requests your view! Post a comment on "NCE Product Pipeline". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

    Aug 8, 2017

    'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    RANBAXY LAB SHARE PRICE


    Apr 1, 2015 (Close)

    TRACK RANBAXY LAB

    • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    MARKET STATS